InterMune Announces Publication of Pricing and Reimbursement Conditions for Esbriet® (pirfenidone) in Italy

InterMune, Inc. (NASDAQ: ITMN ) today announced that the Board of the Italian Drug Agency (AIFA) has approved the pricing and reimbursement conditions for Esbriet^® (pirfenidone), and that the agreement has been published in the Official Gazette, the official journal of the government of Italy. Esbriet is InterMune's product for the treatment of adult